Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia

NCT06767683 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT06767683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06767683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia
Lead sponsor
Alkermes, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
January 27, 2025
Completion date
June 30, 2030
Enrollment
786 (estimated)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic hypersomnia, narcolepsy type 1, narcolepsy type 2